Introduction:
Pharma stock achieved a significant milestone as its subsidiary received the Certificate of Suitability (CEP) from the European Directorate for Octreotide API, strengthening its peptide portfolio and showcasing its commitment to global quality standards in pharmaceutical development and production.
Share price movement of Shilpa Medicare Limited:
On November 19, 2024, Shilpa Medicare Limited opened at ₹890.00, marking a 3.1% increase from its previous close of ₹863.25. The stock reached an intraday high of ₹917.70 and a low of ₹880.35, reflecting strong market activity.
By 12:00 PM, the stock was trading at ₹892.25, registering a 3.36% gain. The market capitalization stands at ₹8,725.39 crore, highlighting positive investor sentiment and confidence in the company.
Why did Shilpa Medicare Limited share price up by 6%?
Shilpa Pharma Lifesciences Limited, a 100% subsidiary of Shilpa Medicare Limited, has received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its Active Pharmaceutical Ingredient (API), Octreotide, marking a significant milestone in its operations.
Octreotide, a synthetic peptide produced through solid-phase synthesis, is used to treat acromegaly, severe diarrhea or flushing episodes from metastatic carcinoid tumours, and profuse watery diarrhea caused by Vasoactive Intestinal Peptide (VIP) secreting tumours. This advancement adds to Shilpa’s growing peptide portfolio.
As the second peptide molecule in its portfolio, the CEP reflects Shilpa Pharma Lifesciences’ dedication to quality-oriented development and production. The certification highlights the company’s ability to meet global quality standards, enhancing its reputation and market position in the pharmaceutical industry.
Recent news about Shilpa Medicare Limited:
As of November 14, Shilpa Medicare Limited has reported a substantial increase in its consolidated net profit for the second quarter of fiscal year 2025, ending September 30, 2024.
The company’s net profit surged by 1,042.68% to ₹17.94 crore, compared to the same period in the previous year. This remarkable growth was accompanied by a 9.85% rise in revenue from operations, totaling ₹343.80 crore for the quarter.
Also Read: Auto ancillary stock jumps 5.3% after company to supply drive train parts for BMW’s EV sports cars
Ace investor holding of Shilpa Medicare Limited:
Akash Bhanshali:
Ace investor Akash Bhanshali is known for his strategic investments in high-growth potential companies. Currently holding 1.55% in Shilpa Medicare Ltd, he owns 15,11,083 shares valued at ₹891.45 each, reflecting his focus on identifying promising opportunities in the pharmaceutical sector.
Viral Amal Parikh:
Ace investor Viral Amal Parikh is renowned for his sharp investment strategies. Currently, he holds 1.02% in Shilpa Medicare Ltd., owning 10,00,000 shares at ₹892.95 each, showcasing his focus on high-potential pharmaceutical stocks and a keen eye for value-driven opportunities.
Stock performance of Shilpa Medicare Limited for Period of 1 week, 6 months and 1 year:
Shilpa Medicare Limited’s stock showed a minor decline of -1.40% over the past week. However, it delivered impressive returns of 70.9% over six months and an outstanding 135% over the past year, reflecting strong growth potential and investor confidence in the pharmaceutical sector.
Also Read: Smallcap stock jumps 15% after company forays into EV and Li-ion battery assembly
Shareholding pattern of Shilpa Medicare Limited:
| All values in % | Sep-24 | Jun-24 | Mar-24 |
| Promoters | 44.33 | 44.39 | 50.01 |
| FII | 9.59 | 9.08 | 5.63 |
| DII | 8.18 | 7.61 | 1.65 |
| Public | 37.9 | 38.91 | 42.71 |
About Shilpa Medicare Limited:
Shilpa Medicare Limited is a leading pharmaceutical company specialising in APIs, oncology, and niche therapeutics. With a strong global presence, it focuses on innovation, quality, and sustainability, catering to international markets and advancing healthcare through its extensive product portfolio and cutting-edge manufacturing facilities.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
